Compare Citius Pharmaceuticals Inc (CTXR) vs Emerson Electric Co. (EMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Emerson Electric Co. — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Emerson Electric Co. trades at $136.24 (market cap $76.22B). The key difference: Emerson Electric Co. is far larger — about 5206.3× Citius Pharmaceuticals Inc's market cap, and Emerson Electric Co. pays a 1.63% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | EMR | |
|---|---|---|
Market Cap | $14.64M | $76.22B |
Sector | Health | Industrials |
52-Week High | $1.82 | $161.69 |
52-Week Low | $0.53 | $123.30 |
Enterprise Value | $10.86M | $88.49B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Emerson Electric (EMR) trades at $135.38, down 2.52% on the day, with a bearish technical signal and mixed earnings history. The stock shows moderate valuation ratios (P/E 31.34, P/S 4.17) and stable profitability (net margin 13.35%). Recent news highlights upcoming Q3 2026 earnings and dividend activity, while cash flow trends indicate operational strength but net outflows.
The outlook is cautiously optimistic with a consensus price target of $157.60 (16.4% upside), supported by analyst buy ratings (51.2%). Key risks include volatile cash flows and competitive pressures in manufacturing electronics. Earnings growth and sector momentum remain catalysts for potential appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
